Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.43 |
| ▸ | KDM4A | O75164 | 11/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099837 | 0.82 | KDM4C (0.42) | ALDH1A1TDP1KDM4CKDM4APHF8 | |
| SCHEMBL14944834 | 0.72 | KDM4C (0.43) | ALDH1A1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL14944835 | 0.72 | ALDH1A1 (0.47) | ALDH1A1TDP1KDM4A | |
| SCHEMBL13318882 | 0.66 | ALDH1A1 (0.45) | ALDH1A1TDP1 | |
| SCHEMBL6061060 | 0.66 | ALDH1A1 (0.57) | ALDH1A1TDP1PHF8KDM2ACA2 | |
| Methyl Isobutyl Ketone SCHEMBL15458 | 0.66 | — | — | |
| Methyl Isobutyl Ketone SCHEMBL1128055 | 0.66 | ALDH1A1 (1.00) | ALDH1A1TDP1CA2 | |
| Methyl Isobutyl Ketone SCHEMBL1580340 | 0.66 | — | — | |
| SCHEMBL21765708 | 0.64 | ALDH1A1 (0.48) | ALDH1A1TDP1PHF8KDM2ACA2 | |
| SCHEMBL801270 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | ALDH1A1 1149/4885TDP1 1246/4885KDM4C 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.